Randomized trial shows finerenone significantly slows kidney function decline in chronic kidney disease — Evidence Review
Published in New England Journal of Medicine, by researchers from University Medical Center Groningen
Researched by
— the AI search engine for science
Table of Contents
A large international clinical trial found that finerenone significantly slowed kidney function loss in non-diabetic chronic kidney disease (CKD) patients, suggesting a new treatment option for a group with limited therapies. Related studies largely support these findings, showing finerenone’s benefits in slowing CKD progression and reducing cardiovascular risk, primarily in patients with diabetes.
- The new study demonstrates that finerenone slows estimated glomerular filtration rate (eGFR) decline and reduces cardiovascular and kidney complications in non-diabetic CKD patients, complementing earlier research showing similar benefits in patients with type 2 diabetes 1 2 3.
- Meta-analyses and randomized trials have consistently found that finerenone reduces the risk of kidney disease progression and cardiovascular events, but prior research mostly focused on diabetic populations, leaving a gap now addressed by this study 1 2 3.
- Related studies confirm the clinical relevance of moderate eGFR decline as a surrogate endpoint and underscore the importance of reducing proteinuria, both of which were improved by finerenone in this new trial 5 6.
Study Overview and Key Findings
Chronic kidney disease (CKD) affects hundreds of millions worldwide, and while substantial progress has been made in treating diabetic CKD, options for non-diabetic patients have remained limited. This new large-scale randomized controlled trial, led by researchers at the University Medical Center Groningen, addresses this unmet need by evaluating the impact of finerenone in adults with CKD who do not have diabetes. The study's findings have important implications for expanding the scope of kidney and cardiovascular protection in CKD management, particularly for a population underserved by current guidelines.
| Property | Value |
|---|---|
| Organization | University Medical Center Groningen |
| Journal Name | New England Journal of Medicine |
| Authors | Hiddo Lambers Heerspink |
| Population | Adults with chronic kidney disease without diabetes |
| Sample Size | n=1,584 |
| Methods | Randomized Controlled Trial (RCT) |
| Outcome | Kidney function decline, major kidney events, cardiovascular complications |
| Results | Finerenone slowed eGFR decline by a significant margin. |
Literature Review: Related Studies
To place these findings in context, we searched the Consensus paper database, which contains over 200 million research papers. The following search queries were used to identify relevant literature:
- finerenone kidney function preservation
- eGFR decline treatment options
- chronic kidney disease drug effects
Related Studies Table
| Topic | Key Findings |
|---|---|
| What is the effect of finerenone on CKD progression and cardiovascular outcomes? | - Finerenone reduces the risk of kidney disease progression and cardiovascular events in CKD patients with type 2 diabetes 1 2 3. - Meta-analyses confirm consistent benefit across a broad spectrum of CKD severity in diabetic populations, but evidence in non-diabetic patients was previously lacking 2 3. |
| How reliable are eGFR decline and proteinuria as surrogate endpoints in CKD trials? | - Lesser declines in eGFR (e.g., 40% vs. 57%) are supported as surrogate endpoints for kidney outcomes, with moderate eGFR reductions predicting lower risk of end-stage kidney disease (ESKD) 5 6. - Reductions in urinary protein (albuminuria) are associated with improved renal prognosis and are used as early indicators of treatment efficacy 5 6. |
| Are there safety or pharmacokinetic concerns with finerenone and other drugs in CKD? | - Finerenone has a generally favorable safety profile, though increased risk of hyperkalemia is observed; similar safety findings are reported for other CKD and heart failure therapies 1 2 3 4. - CKD alters drug metabolism and increases the risk of adverse drug reactions, emphasizing the need for careful monitoring and individualized therapy 11 12 13. |
| What are the treatment options and challenges for non-diabetic CKD? | - Most prior therapies (e.g., ACE inhibitors, ARBs) provide benefit but do not fully address CKD progression in non-diabetic patients 9. - Analgesic use is common in CKD and is associated with significant adverse outcomes, highlighting the need for safer disease-modifying agents 10 14. |
What is the effect of finerenone on CKD progression and cardiovascular outcomes?
Previous studies have established that finerenone reduces the risk of CKD progression and cardiovascular events in patients with type 2 diabetes and CKD 1 2 3. The majority of this evidence comes from large-scale RCTs and pooled meta-analyses, but until now, data in non-diabetic CKD patients were lacking. The new study expands the evidence base by confirming similar benefits for a non-diabetic population, broadening the drug’s potential impact.
- Finerenone consistently lowers the risk of kidney and cardiovascular outcomes in diabetic CKD populations 1 2 3.
- Meta-analyses show these benefits are robust across various stages of CKD, but most included only diabetic patients 2 3.
- The new trial demonstrates that these protective effects also extend to non-diabetic CKD, filling a critical gap in evidence.
- Prior to this study, non-diabetic CKD patients had few proven options beyond ACE inhibitors or ARBs 9.
How reliable are eGFR decline and proteinuria as surrogate endpoints in CKD trials?
The use of eGFR decline and reductions in proteinuria as surrogate endpoints is well-validated in kidney disease trials 5 6. Both endpoints are strongly associated with the risk of ESKD and are considered meaningful indicators of treatment efficacy. The new study’s focus on eGFR slope and proteinuria reduction aligns with these recommendations, supporting the clinical relevance of its outcomes.
- Moderate eGFR declines (30-40%) reliably predict kidney failure risk and are accepted surrogate endpoints in clinical trials 5.
- Slower eGFR decline over 2-3 years is associated with a lower risk of progressing to ESKD, even in early-stage CKD 6.
- Reductions in urinary protein (albuminuria) are early signs of kidney protection and improved prognosis 5 6.
- The magnitude of proteinuria reduction achieved with finerenone in the new study is clinically meaningful.
Are there safety or pharmacokinetic concerns with finerenone and other drugs in CKD?
Finerenone is generally well tolerated, with hyperkalemia as the most notable adverse event, a trend seen with other mineralocorticoid receptor antagonists 1 2 3 4. However, CKD itself alters the metabolism and clearance of many drugs, raising the risk of adverse reactions. This necessitates individualized dosing and careful monitoring.
- In both diabetic and non-diabetic populations, finerenone’s safety profile is similar to placebo, aside from a higher incidence of hyperkalemia 1 2 3.
- Studies highlight that CKD increases the risk of drug interactions and adverse reactions, especially with polypharmacy 11 12 13.
- Non-steroidal anti-inflammatory drugs (NSAIDs) and opioids are commonly used in CKD but pose significant risks, reinforcing the need for safer disease-modifying agents 10 14.
- Optimizing drug dosing in CKD is complex due to altered metabolism and pharmacokinetics.
What are the treatment options and challenges for non-diabetic CKD?
Therapeutic options for non-diabetic CKD have been limited, with ACE inhibitors or ARBs as standard care but incomplete in preventing progression. Analgesic drugs, often used for symptom control, are associated with significant harm, underlining the need for new disease-modifying treatments like finerenone.
- Most large trials of CKD therapies have focused on diabetic populations, leaving a gap for non-diabetic patients 1 2 3.
- Chronic use of analgesics is prevalent in CKD and is linked to adverse outcomes, including increased mortality and hospitalization 10 14.
- The new study offers evidence for a safe, effective disease-modifying therapy for non-diabetic CKD.
- Continued use of ACE inhibitors or ARBs in advanced CKD may provide cardiovascular benefits without excessive risk for ESKD 9.
Future Research Questions
While this study advances the field by demonstrating finerenone’s benefits in non-diabetic CKD, several important questions remain. Further research is needed to clarify long-term outcomes, optimal patient selection, comparative effectiveness with other therapies, and safety in broader real-world populations. Addressing these gaps will help refine treatment strategies for CKD.
| Research Question | Relevance |
|---|---|
| What are the long-term effects of finerenone in non-diabetic CKD? | Long-term safety and efficacy data are needed to assess whether short-to-medium term benefits translate into durable protection against ESKD and cardiovascular disease 1 3 6. |
| How does finerenone compare to SGLT2 inhibitors in non-diabetic CKD? | Comparative trials are warranted to determine relative efficacy, safety, and potential additive effects of finerenone versus other emerging therapies such as SGLT2 inhibitors 8. |
| What patient subgroups benefit most from finerenone in CKD? | Identifying which CKD phenotypes or comorbidities respond best to finerenone can guide personalized therapy and optimize outcomes 3 4. |
| What are the risks of adverse drug reactions with finerenone in polypharmacy CKD patients? | Polypharmacy is common in CKD and increases the risk of drug-drug interactions and adverse events, necessitating real-world safety data for finerenone in complex regimens 11 12. |
| Can proteinuria reduction with finerenone predict long-term renal outcomes in non-diabetic CKD? | Validating proteinuria reduction as a surrogate for hard renal outcomes in non-diabetic CKD will clarify the clinical significance of early treatment effects 5 6. |